1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Scandinavian Real Heart AB

Scandinavian Real Heart AB

SSTO:HEART
16.70
SEK
0.00
(0.00%)
69.48MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
0.88
0.58
0.47
2.26
- -
- -
- -
- -
0.01
- -
- -
- -
- -
Basic EPS, GAAP
-1
-6.58
-5.96
-13.7
-40.17
-26.37
-17.16
-16.94
-14.08
-18.79
-46.79
-16.55
-7.08
- -
Free Cash Flow per Basic Share
- -
-10.17
-14.08
-34.12
-52.33
-42.62
-58.79
-46.42
-39.28
-41.83
-18.46
-19.92
-8.76
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
2.11
29.17
23.22
57.14
80.43
57.47
138.88
137.65
149.51
131.18
56.47
32.45
12.46
12.46
Tangible Book Value per Share
-2.83
21.05
6.71
20.66
38.26
-7.71
46.72
34.24
50.9
-9.95
17.82
5.08
1.86
1.86
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
2
5
3
Sales/Revenue/Turnover
- -
- -
- -
- -
1
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-53,327.77
-734.68
-1,021.04
-2,867.53
-1,285.35
- -
- -
- -
- -
-128,463.16
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
-2
-2
-4
-14
-9
-7
-9
-10
-14
-68
-34
-35
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-58,133.18
-747.03
-1,033.75
-2,927.54
-1,773.51
- -
- -
- -
- -
-139,879.11
- -
- -
- -
- -
Working Capital
- -
6
2
8
17
1
22
20
40
-6
32
14
11
11
LT Debt
- -
- -
- -
3
4
3
3
3
2
2
6
4
3
3
Total Equity
1
7
6
16
28
19
59
72
111
98
82
67
62
62
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-38.45
-42.05
-22.73
-35.04
-62.87
-37.84
-18.62
-13.5
-11.46
-13.39
-75.66
-45.99
-54.68
- -

Capital Structure

SEK

•

in mil. unless spec.
Mar'25
Jun'25
Dec'25
ST Debt
2
2
2
LT Borrowings
4
4
3
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
4
5
Market Capitalization
32
64
69

Working Capital

SEK

•

in mil. unless spec.
Mar'25
Jun'25
Dec'25
Total Current Assets
14
30
18
Cash, Cash Equivalents & STI
11
28
17
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
9
10
7
Payables & Accruals
- -
- -
- -
ST Debt
2
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
44.06%
0.37%
-7.2%
Free Cash Flow
37.77%
14.81%
6.29%
Net Income, GAAP
76.75%
78.42%
3.34%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

SEK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Semi-annual Earnings Per Share

SEK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-16.55
2025
- -
- -
-7.08
2026
- -
- -
- -

Semi-annual Dividends Per Share

SEK

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ina Laura Perkins
Full Time Employees
15
Sector
Health technology
Industry
Medical specialties
Address
Kopparbergsvägen 6 Västerås VM Sweden 722 13
IPO Date
Nov 26, 2014
Website
realheart.se
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Scandinavian Real Heart AB (Publ) Scandinavian Real Heart AB (Publ) (HEART.ST) develops artificial heart technologies and related medical devices to treat advanced heart failure patients awaiting transplants; its flagship product, Realheart TAH, is a total artificial heart that mimics the human heart's shape, function, and pulsating blood flow pattern; additional products in development include RealVAD, a pulsating left ventricular assist device, PulsePump for generating pulsating flow in heart-lung machines to protect vital organs during surgery, and Sternal Prosthesis to securely fixate the sternum post-open chest surgery, reducing healing time and complications. The company, founded in 2007 after initial research began in 1999 and headquartered in Västerås, Sweden, operates primarily in the medtech sector with a focus on biomedical engineering for cardiovascular applications and targets healthcare providers and patients with severe heart conditions globally. Recent developments include patent approvals granted in China and Japan in November 2025; receipt of approximately SEK 6.8 million from the European Innovation Council following a directed share issue; a Vinnova grant for assembly processes; a directed share issue of up to SEK 32 million; a proposed rights issue of about SEK 70 million for continued financing; and board chairman Oskar Mellgren's acquisition of 7,200 shares on November 24, 2025.